G47ΔhIL12A Oncolytic HSV for Glioblastoma and Triple-Negative Breast Cancer Treatment
Summary
USPTO published patent application US20260097135A1 for G47ΔhIL12A, an oncolytic herpes simplex virus (oHSV) engineered with human IL-12 transgene driven by HCMV IE enhancer/promoter. The invention addresses augmented transgene production and increased virus replication while maintaining safety profiles. Applications include treatment of glioblastoma (GBM) and triple-negative breast cancer (TNBC). Filing date: September 26, 2023; Application No. 19114912.
What changed
USPTO published patent application US20260097135A1 disclosing G47ΔhIL12A, a modified oncolytic herpes simplex virus expressing human IL-12 under HCMV immediate-early enhancer/promoter control. The invention demonstrates augmented transgene expression and enhanced viral replication while retaining safety characteristics. The virus is designed for treating solid tumors including glioblastoma and triple-negative breast cancer.
Pharmaceutical and biotechnology companies developing oncolytic viral therapies should monitor this application's prosecution. The broad claim scope covering both GBM and TNBC indications may affect freedom-to-operate analyses for competing oHSV programs. Research institutions and trial sponsors investigating IL-12 armed oncolytic viruses for cancer should evaluate potential overlap with disclosed methods.
What to do next
- Monitor patent prosecution for examiner actions
- Review claims for freedom-to-operate analysis
- Assess IP protection strategy for oncology therapeutics
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS (oHSV) AND METHODS OF USE THEREOF
Application US20260097135A1 Kind: A1 Apr 09, 2026
Inventors
Robert L. Martuza, Samuel D. Rabkin, Dipongkor Saha, Nusrat Jahan
Abstract
Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer/promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).
CPC Classifications
A61K 48/0066 A61K 38/208 A61K 45/06 C12N 15/86 C12N 2710/16643 C12N 2710/16662
Filing Date
2023-09-26
Application No.
19114912
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.